(Q51590425)
Statements
1 reference
Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. (English)
1 reference
Norman Putzki
1 reference
Ozgür Yaldizli
1 reference
Robert Bühler
1 reference
Guido Schwegler
1 reference
Daniela Curtius
1 reference
Barbara Tettenborn
1 reference
16 January 2010
1 reference
63
1 reference
2
1 reference
101-106
1 reference
Identifiers
1 reference
1 reference